Advertisement

CNS Drugs

, Volume 24, Issue 9, pp 721–728 | Cite as

Role of Zinc in the Pathogenesis of Attention-Deficit Hyperactivity Disorder

Implications for Research and Treatment
  • Peter Lepping
  • Markus Huber
Current Opinion

Abstract

The dopamine transporter is regulated by zinc (Zn2+), which directly interacts with the transporter protein as a potent non-competitive blocker of substrate translocation (dopamine transport inward and outward). The fact that dysfunction of the dopamine transporter is involved in the pathogenesis of attention-deficit hyperactivity disorder (ADHD) is interesting in the context of studies that suggest the involvement of zinc deficiency in patients with ADHD. In this article, we present a hypothesis exploring the causative mechanism of zinc deficiency in ADHD and why zinc might be beneficial as a supplementary medication and/or adjunct to psychostimulants (methylphenidate, amfetamine) in zinc-deficient ADHD patients. The hypothesis is based on published in vitro observations that the human dopamine transporter contains a high-affinity zinc binding site (His-193, His-375, Glu-396) on its extracellular face that modulates transporter function, and in vivo studies suggesting that response to stimulants is reduced in zinc-deficient ADHD patients. It seems likely that zinc supplementation in zinc-deficient ADHD patients improves the binding status of insufficiently occupied zinc binding sites on the dopamine transporter. We propose to test our hypothesis by recruiting zinc-deficient ADHD patients who will undergo positron emission tomography with the 11C-raclopride displacement method to investigate whether zinc increases extracellular dopamine levels.

Keywords

Cocaine Methylphenidate Zinc Deficiency Dopamine Transporter Zinc Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

PL has received honoraria for educational talks in the last 5 years from Eli Lily, Otsuka and AstraZeneca. MH has nothing to declare.

Both authors contributed equally to the manuscript (other contributors, including medical writers and editors, were not involved). No sources of funding were obtained to assist with the preparation of this article.

References

  1. 1.
    Torres GE. The dopamine transporter proteome. J Neurochem 2006; 97 Suppl. 1: 3–10PubMedCrossRefGoogle Scholar
  2. 2.
    Norregaard L, Frederiksen D, Nielsen EO, et al. Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J 1998; 17: 4266–73PubMedCrossRefGoogle Scholar
  3. 3.
    Scholze P, Norregaard L, Singer EA, et al. The role of zinc ions in reverse transport mediated by monoamine transporters. J Biol Chem 2002; 277: 21505–13PubMedCrossRefGoogle Scholar
  4. 4.
    Arnold LE, DiSilvestro RA. Zinc in attention deficit hyper-activity disorder. J Child Adolesc Psychopharmacol 2005; 15: 619–27PubMedCrossRefGoogle Scholar
  5. 5.
    Sambhi RS, Lepping P. Adult ADHD and psychosis: a review of literature and two cases. Clin Neuropsychiatr 2009; 6: 174–8Google Scholar
  6. 6.
    Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005 Jun 9; 3: 5PubMedCrossRefGoogle Scholar
  7. 7.
    Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess cost of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005; 21: 195–206PubMedCrossRefGoogle Scholar
  8. 8.
    Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194: 204–11PubMedCrossRefGoogle Scholar
  9. 9.
    Spencer TJ. ADHD treatment across the life cycle. J Clin Psychiatry 2004; 65 Suppl. 3: 22–6PubMedGoogle Scholar
  10. 10.
    Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyper-activity disorder. J Atten Disord 2002; 5: 189–202PubMedCrossRefGoogle Scholar
  11. 11.
    Golup MS, Takeuchi PT, Keen CL, et al. Activity and attention in zinc-deprived adolescent monkeys. Am J Nutr 1996; 64: 908–15Google Scholar
  12. 12.
    Agget PJ, Harries JT. Current status of zinc in health and disease states. Arc Dis Child 1979; 54: 909–17CrossRefGoogle Scholar
  13. 13.
    Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 181–90PubMedCrossRefGoogle Scholar
  14. 14.
    Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry 2004; 4: 9PubMedCrossRefGoogle Scholar
  15. 15.
    Arnold LE, Pinkham SM, Votolato N. Does zinc moderate essential fatty acid and amphetamine treatment of attention deficit hyperactivity disorder? J Child Adolesc Psychopharmacol 2000; 10: 111–7PubMedCrossRefGoogle Scholar
  16. 16.
    Rogers JM, Keen CL, Hurley LS. Zinc, copper, and manganese deficiencies in prenatal and neonatal development, with special reference to the central nervous system. In: Gabay S, Harris J, Ho BT, editors. Metal ions in neurology and psychiatry. New York: Liss, 1985: 3–34Google Scholar
  17. 17.
    Young GS, Conquer JA, Thomas R. Effect of randomized supplementation with high dose olive, flax or fish oil on serum phospholipid fatty acid levels in adults with attention deficit hyperactivity disorder. Reprod Nutr Dev 2005; 45: 549–58PubMedCrossRefGoogle Scholar
  18. 18.
    Matsudaira T. Attention deficit disorders: drugs or nutrition? Nutr Health 2007; 19: 57–60PubMedCrossRefGoogle Scholar
  19. 19.
    Newmark SC. Nutritional intervention in ADHD. Explore (NY) 2009; 5: 171–4CrossRefGoogle Scholar
  20. 20.
    Chalon S. The role of fatty acids in the treatment of ADHD. Neuropharmacology 2009; 57: 636–9PubMedCrossRefGoogle Scholar
  21. 21.
    Sinn N. Nutritional and dietary influences on attention deficit hyperactivity disorder. Nutr Rev 2008; 66: 558–68PubMedCrossRefGoogle Scholar
  22. 22.
    Sandyk R. Zinc deficiency in attention-deficit hyperactivity disorder. Int J Neurosci 1990; 52: 239–41PubMedCrossRefGoogle Scholar
  23. 23.
    Chen MD, Lin PY, Sheu WH. Zinc coadministration attenuates melatonin’s effect on nitric oxide production in mice. Bio Trace Elem Res 1999; 63: 261–8CrossRefGoogle Scholar
  24. 24.
    Manev H, Uz T. Dosing time-dependent actions of psychostimulants. Int Rev Neurobiol 2009; 88: 25–41PubMedCrossRefGoogle Scholar
  25. 25.
    Hoebert M, van der Heijden KB, van Geijlswjk IM, et al. Long term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res 2009; 47: 1–7PubMedCrossRefGoogle Scholar
  26. 26.
    Bendz LM, Scates AC. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother 2010; 44: 185–91PubMedCrossRefGoogle Scholar
  27. 27.
    Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155: 1325–31PubMedGoogle Scholar
  28. 28.
    Volkow ND, Wang GJ, Fowler JS, et al. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1410–5PubMedCrossRefGoogle Scholar
  29. 29.
    Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237–48PubMedCrossRefGoogle Scholar
  30. 30.
    Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1397–409PubMedCrossRefGoogle Scholar
  31. 31.
    Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 2008; 8: 611–25PubMedCrossRefGoogle Scholar
  32. 32.
    Rommelse NN, Altink ME, Arias-Vasquez A, et al. A review and analysis of the relationship between neuropsychological measures and DAT1 in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1536–46PubMedCrossRefGoogle Scholar
  33. 33.
    Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009; 126: 51–90PubMedCrossRefGoogle Scholar
  34. 34.
    Banaschewski T, Becker K, Scherag S, et al. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry 2010; 19: 237–57PubMedCrossRefGoogle Scholar
  35. 35.
    Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6 Suppl. 1: S31–43PubMedGoogle Scholar
  36. 36.
    Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 2003; 479: 153–8PubMedCrossRefGoogle Scholar
  37. 37.
    Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci 2010; 1187: 316–40PubMedCrossRefGoogle Scholar
  38. 38.
    Fowler JS, Volkow ND, Wang GJ, et al. 11-Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28: 561–72PubMedCrossRefGoogle Scholar
  39. 39.
    Bonnet JJ. Interactions of cations and anions with the binding of uptake blockers to the dopamine transporter. Eur J Pharmacol 2003; 479: 199–212PubMedCrossRefGoogle Scholar
  40. 40.
    Richfield EK. Zinc modulation of drug binding, cocaine affinity states, and dopamine uptake on the dopamine uptake complex. Mol Pharmacol 1993; 43: 100–8PubMedGoogle Scholar
  41. 41.
    Bonnet JJ, Benmansour S, Amejdki-Chab N, et al. Effect of CH3HgCl and several transition metals on the dopamine neuronal carrier; peculiar behavior of Zn2+. Eur J Pharmacol 1994; 266: 87–97PubMedCrossRefGoogle Scholar
  42. 42.
    Loland CJ, Norgaard-Nielsen K, Gether U. Probing dopamine transporter structure and function by Zn2+-site engineering. Eur J Pharmacol 2003; 479: 187–97PubMedCrossRefGoogle Scholar
  43. 43.
    Meinild AK, Sitte HH, Gether U. Zinc potentiates an uncoupled anion conductance associated with the dopamine transporter. J Biol Chem 2004; 279: 49671–9PubMedCrossRefGoogle Scholar
  44. 44.
    Arnold LE, Bozzolo H, Hollway J, et al. Serum zinc correlates with parent- and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15: 628–36PubMedCrossRefGoogle Scholar
  45. 45.
    Kozielec T, Starobrat-Hermelin B, Kotkowiak L. Deficiency of certain trace elements in children with hyperactivity. Psychiatr Pol 1994; 28: 345–53PubMedGoogle Scholar
  46. 46.
    Starobrat-Hermelin B. The effect of deficiency of selected bioelements on hyperactivity in children with certain specified mental disorders [in Polish]. Ann Acad Med Stetin 1998; 44: 297–314PubMedGoogle Scholar
  47. 47.
    Ward NI, Soulsbury KA, Zettel VH, et al. The influence of the chemical additive tartrazine on the zinc status of hyperactive children: a double-blind, placebo-controlled study. J Nutr Med 1990; 1: 51–8CrossRefGoogle Scholar
  48. 48.
    Ward NI. Assessment of chemical factors in relation to child hyperactivity. J Nutr Environ Med (Abingdon) 1997; 7: 333–42CrossRefGoogle Scholar
  49. 49.
    Toren P, Eldar S, Sela BA, et al. Zinc deficiency in attention-deficit hyperactivity disorder. Biol Psychiatry 1996; 40: 1308–10PubMedCrossRefGoogle Scholar
  50. 50.
    Vogt K, Mellor J, Tong G, et al. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 2000; 26: 187–96PubMedCrossRefGoogle Scholar
  51. 51.
    Huber M, Kirchler E, Niederhofer H, et al. Neuropsychiatric bases of the methylphenidate-therapy of the attention deficit/hyperactivity disorder (ADHD) [in German]. Fortschr Neurol Psychiatr 2007; 75: 275–84PubMedCrossRefGoogle Scholar
  52. 52.
    Dewey SL, Smith GS, Logan J, et al. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993; 13: 350–6PubMedCrossRefGoogle Scholar
  53. 53.
    Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methyl-phenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002; 43: 181–7PubMedCrossRefGoogle Scholar
  54. 54.
    Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 932–40PubMedCrossRefGoogle Scholar
  55. 55.
    Langley K, Fowler T, Ford T, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry 2010; 196: 235–40PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Wrexham Academic Department of Mental HealthBetsi Cadwaladr University Health Board and Glyndŵr UniversityWrexhamUK
  2. 2.Department of PsychiatryGeneral Hospital BruneckBruneck, SpitalstrasseItaly

Personalised recommendations